Integrating genomic structural equation modeling and experimental validation to unravel the genetic basis of male genital lichen sclerosus - Scorecard - MDSpire

Integrating genomic structural equation modeling and experimental validation to unravel the genetic basis of male genital lichen sclerosus

  • By

  • Jianbai Chen

  • Zhiming Zhang

  • Qiang Fu

  • Haozhong Hou

  • Gongquan Xu

  • Zhenyu Li

  • Zhiguo Lu

  • Jianxin Qiu

  • Ke Wu

  • Xiaoping Gao

  • Geng Zhang

  • Longfei Yang

  • Rundong Song

  • Wei Zhang

  • July 16, 2026

Share

Clinical Scorecard: Combining Genomic Structural Equation Modeling with Experimental Validation to Explore the Genetic Underpinnings of Male Genital Lichen Sclerosus

At a Glance

CategoryDetail
ConditionMale Genital Lichen Sclerosus (MGLSc)
Key MechanismsGenetic architecture, immune-related loci, polygenic risk score analysis
Target PopulationMales diagnosed with genital lichen sclerosus
Care SettingGenomic and molecular research

Key Highlights

  • 208 SNPs reached genome-wide significance for MGLSc.
  • HLA-DPA1 identified as a high-confidence susceptibility gene.
  • Integration of Genomic-SEM with multi-omics analyses.
  • Identification of 43 risk loci and 14 candidate genes.
  • Significant downregulation of immune-related genes in MGLSc samples.

Guideline-Based Recommendations

Diagnosis

  • Diagnosis based on clinical symptoms including male sexual dysfunction, pruritus, and cutaneous lesions.

Management

  • Further mechanistic and translational studies are suggested to explore identified genetic factors.

Monitoring & Follow-up

  • Monitor gene expression levels of prioritized genes in MGLSc samples.

Risks

  • Potential autoimmune mechanisms and immune dysregulation are implicated in MGLSc pathogenesis.

Patient & Prescribing Data

Males with chronic inflammatory skin disorders, specifically MGLSc.

No specific treatment insights provided; focus on genetic understanding.

Clinical Best Practices

  • Utilize genomic data to inform understanding of MGLSc.
  • Incorporate findings from GWAS and transcriptomic studies in clinical assessments.

Related Resources & Content

Original Source(s)

Related Content